The nausea timeline across the first four weeks, with a tabulated log — what changed since

On the subject in the title: The nausea timeline across the first four weeks, with a tabulated log — what changed since Working notes rather than a conclusion.

I have read the maintained page on this and I still have a gap, so I am asking rather than guessing.

Context: retatrutide, 6 weeks in, currently at a dose I reached by the standard four-week steps. Everything below is my own record rather than anything a clinician told me.

The specific question is the one in the title. What I have already checked: the labelling summary on the relevant documentation page, the two most-linked topics in this subcategory, and my own notes from the last 13 weeks. What I could not find is whether the answer changes at higher doses or whether it is the same arithmetic throughout.

If the answer is "it depends", I would rather know what it depends on than be given a number.

Coming back to the opening post, because the follow-up matters more than the original answer.

Pancreatitis: a rare but serious event with a specific presentation (epigastric pain, back pain, elevated lipase). If this constellation of findings appears, stopping the drug and seeking immediate evaluation is appropriate. Do not interpret this as "likely" — it is rare — but recognize the pattern if it appears.

Delayed gastric emptying: the mechanism behind much of the gastrointestinal side-effect profile. At extreme magnitudes, severe gastroparesis is a rare but serious complication. Distinguishing ordinary gastrointestinal effects from the rare severe end is a clinical judgement.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

This follows post #2 rather than contradicting it.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

Fatigue: commonly reported, frequently multifactorial. It is worth asking whether other factors have changed (sleep, training volume, diet adequacy, hydration) before attributing all of it to the compound. Some fatigue resolves with time; some persists.

Hair shedding: telogen effluvium associated with rapid weight loss is reported. The timing usually correlates with the speed of weight change rather than the compound specifically. It is usually self-limiting.

Worth separating two things that post #4 runs together.

Lean mass loss: the rate of lean tissue loss depends on protein intake, resistance training volume, and total energy deficit. Adequate protein and maintaining training intensity both help preserve lean mass during weight reduction.

Timeline matters: onset, duration, pattern over days or weeks, relationship to injection and to meals all provide information that "I have nausea" does not. Posting those details gets better responses than reporting the symptom alone.

Nausea: the most common side effect and the most dose- and titration-dependent one. It is usually most prominent in the first 24 to 48 hours after injection and attenuates as the dose is held stable. At each escalation step it often resets briefly before attenuating again.

On post #7 — agreed on the reasoning, with one qualification.

Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.

post #11 answers the question as asked. The question underneath it is different.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

Constipation: common, manageable, and frequently under-reported because it is not dramatic. Increasing fibre and fluid intake helps. Over-the-counter management is usually effective. This is worth addressing proactively rather than waiting for it to worsen.

Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during titration is ordinary. Persistent vomiting or vomiting of a new character later in treatment warrants contact with your clinician.